Efficacy Analysis of Unrelated Umbilical Cord Blood Transplantation for the Treatment of Wiskott-Aldrich Syndrome.
10.7534/j.issn.1009-2137.2018.06.039
- Author:
Hui-Hui SONG
1
;
Zheng-Ping YU
1
;
Wen-Duo HEG
1
;
Jia-Hua DING
2
;
Bao-An CHEN
1
Author Information
1. Department of Hematology，Zhongda Hospital，Southeast University，Nanjing 210009，Jiangsu Province, China.
2. Department of Hematology，Zhongda Hospital，Southeast University，Nanjing 210009，Jiangsu Province, China.E-mail: 101007972@seu.edu.cn.
- Publication Type:Journal Article
- MeSH:
Cord Blood Stem Cell Transplantation;
Graft vs Host Disease;
Humans;
Infant;
Infant, Newborn;
Male;
Retrospective Studies;
Transplantation Conditioning;
Treatment Outcome;
Wiskott-Aldrich Syndrome
- From:
Journal of Experimental Hematology
2018;26(6):1816-1821
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To explore the clinical efficacy and safety of unrelated umbilical cord blood transplantation (UCBT) for the treatment of Wiskott-Aldrich syndrome(WAS).
METHODS:Five pediatric patients with WAS received single UCBT were retrospectively analyzed. The median age of these male patients was 268 days (range, 3 days -695 days). Among them, 2 patients were transplanted with a 6/6 matched cord blood graft，the other 3 patients received a 5/6 matched cord blood graft. Myeloablative conditioning regimen was applied, and all patients received a combination of cyclosporine and mycophenolate mofetil for the prophylaxis of graft versus host disease (GVHD). The recovery time of neutrophils and platelets as well as chimerism after transplantation were taken as the evidence of hematopoietic reconstruction.
RESULTS:All the five pediatric patients had hematopoietic recovery. A median time of neutrophil cells after transplantation was at 15.8 days (range,11 days -25 days), and platelet recovery was at a median of 20.4 days(range,12 days-30 days). Chimerism data were available for 5 patients at 30 days after UCBT, 4 out of the 5 patients had full donor chimerism and only one patient had mixed chimerism. There were 2 cases with pre-engraftment syndrome, 3 cases with acute GVHD gradeⅠ-Ⅲ, 4 cases with pulmonary infection and cytomegalovirus infection, but chronic GVHD was not observed in 5 cases. Four patients were alive with a median follow-up of 12.3 months (range, 5 months-17 months), and one patient had died at 22 days after UCBT.
CONCLUSION:Unrelated umbilical cord blood transplantation is a safe and effective treatment method for Wiskott-Aldrich syndrome.
